The efficacy and safety of wedge resection for peripheral stage IA lung adenocarcinoma: a real-world study based on a single center

被引:3
|
作者
Bian, Dongliang [1 ]
Xiong, Yicheng [1 ]
Jin, Kaiqi [1 ]
Zhu, Yuming [1 ]
Yu, Huansha [2 ]
Dai, Jie [1 ]
Jiang, Gening [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Anim Expt Ctr, Shanghai, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
Lung adenocarcinoma stage IA; wedge resection; recurrence; SECTION COMPUTED-TOMOGRAPHY; LIMITED RESECTION; SUBLOBAR RESECTION; SURVIVAL OUTCOMES; CANCER; LOBECTOMY; IMPACT; CLASSIFICATION;
D O I
10.21037/jtd-22-1010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The effectiveness of segmentectomy for stage IA lung adenocarcinoma (IA-LUAD) has been well-documented. However, the efficacy and safety of wedge resection for peripheral IA-LUAD remains controversial. This study evaluated the feasibility of wedge resection in patients with peripheral IA-LUAD. Methods: Patients with peripheral IA- LUAD who underwent wedge resection by video- assisted thoracoscopic surgery (VATS) at Shanghai Pulmonary Hospital were reviewed. Cox proportional hazards modeling was performed to identify predictors of recurrence. Receiver operating characteristic (ROC) curve analysis was used to calculate the optimal cutoffs of identified predictors. Results: A total of 186 patients (female/male, 115/ 71; mean age, 59.9 years) were included. Mean maximum dimension of consolidation component (MCD) was 5.6 mm, consolidation-to-tumor ratio (CTR) was 37%, and mean computed tomography value of tumor (CTVt) was -285.4 HU. With a median follow-up of 67 months (interquartile range, 52-72 months), the 5-year recurrence rate was 4.84%. Ten patients occurred recurrence postoperatively. No recurrence was observed adjacent to the surgical margin. Increasing MCD, CTR, and CTVt were associated with a higher risk of recurrence, with corresponding hazard ratios (HRs) of 1.212 [95% confidence interval (CI): 1.120-1.311], 1.054 (95% CI: 1.018-1.092), and 1.012 (95% CI: 1.004-1.019) with optimal cutoffs for predicting recurrence of 10 mm, 60%, and -220 HU, respectively. When a tumor had characteristics under these respective cutoffs, no recurrence was observed. Conclusions: Wedge resection can be considered to be a safe and efficacious management strategy for patients with peripheral IA-LUAD, especially for MCD less than 10 mm, CTR less than 60% and CTVt less than -220 HU.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 50 条
  • [1] Limited resection for stage IA radiologically invasive lung cancer: a real-world nationwide database study
    Soh, Junichi
    Toyooka, Shinichi
    Shintani, Yasushi
    Okami, Jiro
    Ito, Hiroyuki
    Ohtsuka, Takashi
    Morig, Takeshi
    Watanabe, Shun-Ichi
    Asamura, Hisao
    Chida, Masayuki
    Endo, Shunsuke
    Nakanishi, Ryoichi
    Kadokure, Mitsutaka
    Suzuki, Hidemi
    Miyaoka, Etsuo
    Yoshinon, Ichiro
    Date, And Hiroshi
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2022, 62 (01)
  • [2] Segmentectomy Versus Wedge Resection for Stage IA Lung Adenocarcinoma-A Population-Based Study
    Chiang, Xu-Heng
    Wei, Chih-Fu
    Lin, Ching-Chun
    Lin, Mong-Wei
    Chiang, Chun-Ju
    Lee, Wen-Chung
    Chen, Jin-Shing
    Chen, Pau-Chung
    CANCERS, 2025, 17 (06)
  • [3] Real-world outcomes of lobectomy, segmentectomy and wedge resection for the treatment of stage c-IA lung carcinoma
    Thomas, Pascal Alexandre
    Seguin-Givelet, Agathe
    Pages, Pierre-Benoit
    Alifano, Marco
    Brouchet, Laurent
    Falcoz, Pierre-Emmanuel
    Baste, Jean-Marc
    Glorion, Matthieu
    Belaroussi, Yaniss
    Filaire, Marc
    Heyndrickx, Maxime
    Loundou, Anderson
    Fourdrain, Alex
    Dahan, Marcel
    Boyer, Laurent
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2024, 66 (01)
  • [4] Prognosis of wide wedge resection in patients with stage IA1 and IA2 lung adenocarcinoma with total tumor size including the lepidic component greater than 2 cm: a single center retrospective study
    Moon, Youngkyu
    Choi, Si Young
    Moon, Mi Hyoung
    JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 4731 - 4741
  • [5] Clinical efficacy and safety of adjuvant EGFR-TKIs for resected stage IB lung adenocarcinoma: A real-world study based on propensity score matching
    Shen, Leilei
    Guo, Juntang
    Zhang, Weidong
    Zhang, Lianbin
    Liu, Xi
    Wang, Tao
    Zhang, Tao
    Liang, Chaoyang
    Liu, Yang
    CANCER MEDICINE, 2023, 12 (18): : 18470 - 18478
  • [6] Segmentectomy or Wedge Resection in Stage IA Lung Squamous Cell Carcinoma and Adenocarcinoma?
    Li, Guoshu
    Xie, Shuanshuan
    Hu, Feng
    Tan, Min
    Fan, Lihong
    Wang, Changhui
    JOURNAL OF CANCER, 2021, 12 (06): : 1708 - 1714
  • [7] Prediction of high-grade patterns of stage IA lung invasive adenocarcinoma based on high-resolution CT features: a bicentric study
    Dong, Hao
    Yin, Le-Kang
    Qiu, Yong-Gang
    Wang, Xin-Bin
    Yang, Jun-Jie
    Lou, Cun-Cheng
    Ye, Xiao-Dan
    EUROPEAN RADIOLOGY, 2023, 33 (06) : 3931 - 3940
  • [8] Appropriate Sublobar Resection Choice for Ground Glass Opacity-Dominant Clinical Stage IA Lung Adenocarcinoma Wedge Resection or Segmentectomy
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Nakayama, Haruhiko
    Okumura, Sakae
    Adachi, Shuji
    Yoshimura, Masahiro
    Okada, Morihito
    CHEST, 2014, 145 (01) : 66 - 71
  • [9] Oncologic outcomes of segmentectomy vs lobectomy in pathologic stage IA (≤2 cm) invasive lung adenocarcinoma: A population-based study
    Li, Feng
    Zhao, Yue
    Yuan, Ligong
    Wang, Shuaibo
    Mao, Yousheng
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (07) : 1132 - 1139
  • [10] Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
    Yang, Xue-Ning
    Yan, Hong-Hong
    Wang, Jun
    Chu, Xiang-Yang
    Liu, Zhi-Dong
    Shen, Yi
    Ma, Hai-Tao
    Fu, Xiang-Ning
    Hu, Jian
    Zhou, Nai-Kang
    Liu, Yong-Yu
    Zhou, Xin-Ming
    Li, Jing-Song
    Yang, Kang
    Li, Jian
    Xu, Lin
    Wang, Si-Yu
    Wang, Qun
    Liu, Lun-Xu
    Xu, Shun
    Chen, Zhong-Yuan
    Lou, Hong-He
    Wang, Chang-Li
    Cheng, Ying
    Liu, Si-Yang
    Zhang, Xu-Chao
    Zhong, Wen-Zhao
    Wu, Yi-Long
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):